General Information of Drug Therapeutic Target (DTT) (ID: TT2O84V)

DTT Name Thromboxane A2 receptor (TBXA2R)
Synonyms TXA2-R; TXA2 receptor; Prostanoid TP receptor
Gene Name TBXA2R
DTT Type
Successful target
[1]
BioChemical Class
GPCR rhodopsin
UniProt ID
TA2R_HUMAN
TTD ID
T76198
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MWPNGSSLGPCFRPTNITLEERRLIASPWFAASFCVVGLASNLLALSVLAGARQGGSHTR
SSFLTFLCGLVLTDFLGLLVTGTIVVSQHAALFEWHAVDPGCRLCRFMGVVMIFFGLSPL
LLGAAMASERYLGITRPFSRPAVASQRRAWATVGLVWAAALALGLLPLLGVGRYTVQYPG
SWCFLTLGAESGDVAFGLLFSMLGGLSVGLSFLLNTVSVATLCHVYHGQEAAQQRPRDSE
VEMMAQLLGIMVVASVCWLPLLVFIAQTVLRNPPAMSPAGQLSRTTEKELLIYLRVATWN
QILDPWVYILFRRAVLRRLQPRLSTRPRSLSLQPQLTQRSGLQ
Function
The activity of this receptor is mediated by a G-protein that activates a phosphatidylinositol-calcium second messenger system. In the kidney, the binding of TXA2 to glomerular TP receptors causes intense vasoconstriction. Activates phospholipase C. Isoform 1 activates adenylyl cyclase. Isoform 2 inhibits adenylyl cyclase. Receptor for thromboxane A2 (TXA2), a potent stimulator of platelet aggregation.
KEGG Pathway
Calcium signaling pathway (hsa04020 )
Neuroactive ligand-receptor interaction (hsa04080 )
Platelet activation (hsa04611 )
Reactome Pathway
G alpha (q) signalling events (R-HSA-416476 )
G alpha (12/13) signalling events (R-HSA-416482 )
Thromboxane signalling through TP receptor (R-HSA-428930 )
Prostanoid ligand receptors (R-HSA-391908 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
3 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Alprostadil DMWH7NQ Aorta coarctation Approved [2]
Ridogrel DMWH9CN Acute myocardial infarction BA41 Approved [1]
LAROPIPRANT DM5FABJ Coronary heart disease BA80.Z Phase 4 [3]
------------------------------------------------------------------------------------
11 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ramatroban DMB8UQ3 Perennial allergic rhinitis CA08.03 Phase 2/3 [4]
FK-070 DMJSD5W Angina pectoris BA40 Phase 2 [5]
Ifetroban DMEV39E Aspirin-induced asthma CA23.20 Phase 2 [6]
Ifetroban sodium DMZP84Y Thrombosis DB61-GB90 Phase 2 [7]
KP-496 DMCO8UZ Asthma CA23 Phase 2 [8]
TAK-128 DMHPEFS Diabetic neuropathy 8C0Z Phase 2 [9]
BIBV 308 DMUBMN5 Peripheral vascular disease BD4Z Phase 1 [7]
DT-TX-30 DM1FX09 Angina pectoris BA40 Phase 1 [10]
G-619 DM3H6YC Thrombosis DB61-GB90 Phase 1 [11]
YM-57158 DMS31YW Allergic rhinitis CA08.0 Phase 1 [12]
PGF2alpha DM4XAU7 Solid tumour/cancer 2A00-2F9Z Clinical trial [13]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 Clinical Trial Drug(s)
18 Discontinued Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Domitroban DM3OUWC Thrombosis DB61-GB90 Discontinued in Preregistration [14]
DALTROBAN DMNQIKV N. A. N. A. Discontinued in Phase 3 [15]
Seratrodast DMPNTDL Allergic asthma CA23.0 Discontinued in Phase 3 [16]
Terutroban sodium DMYF1DN Thrombosis DB61-GB90 Discontinued in Phase 3 [17]
ICI-192605 DMY8X6Q Thrombosis DB61-GB90 Discontinued in Phase 2 [18]
Linotroban DM32JL5 Thrombosis DB61-GB90 Discontinued in Phase 2 [19]
SQ-30741 DMTC4VY Thrombosis DB61-GB90 Discontinued in Phase 2 [20]
Z-335 DM2438J Thrombosis DB61-GB90 Discontinued in Phase 2 [21]
CGS-22652 DMF05DL Angina pectoris BA40 Discontinued in Phase 1 [22]
KT2-962 DMBH5G3 Thrombosis DB61-GB90 Discontinued in Phase 1 [23]
KW-3635 DMG068H Thrombosis DB61-GB90 Discontinued in Phase 1 [24]
L-657925 DMOTY3G N. A. N. A. Terminated [25]
ON-579 DMTS6HB Asthma CA23 Terminated [26]
SQ-33961 DMZBQ4I Thrombosis DB61-GB90 Terminated [27]
Sulotroban DM4SVIR Asthma CA23 Terminated [28]
UP-116-77 DMEIR7F Thrombosis DB61-GB90 Terminated [29]
Vapiprost DMJLV03 Cardiovascular disease BA00-BE2Z Terminated [30]
ZT-386 DM193WR Asthma CA23 Terminated [31]
------------------------------------------------------------------------------------
⏷ Show the Full List of 18 Discontinued Drug(s)
27 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
10,10-difluoro TXA2 DML745Y Discovery agent N.A. Investigative [32]
AGN 191976 DMTPV4Y Discovery agent N.A. Investigative [33]
AGN192093 DMISJXB Discovery agent N.A. Investigative [33]
AH23848 DM4S1Y6 Discovery agent N.A. Investigative [13]
BM-573 DMD2H7L Discovery agent N.A. Investigative [34]
butaprost (free acid form) DM5MZHP Discovery agent N.A. Investigative [13]
carbacyclin DMMBQYE Discovery agent N.A. Investigative [13]
carbocyclic thromboxane A2 DMGKSVF Discovery agent N.A. Investigative [35]
cloprostenol DMH01JV Discovery agent N.A. Investigative [13]
EP 171 DM7YION Discovery agent N.A. Investigative [36]
fluprostenol DM9Q2PG Discovery agent N.A. Investigative [13]
I-BOP DMJAPML Discovery agent N.A. Investigative [37]
I-SAP DMJ2FQA Discovery agent N.A. Investigative [38]
M&B 28767 DMJQG82 Discovery agent N.A. Investigative [13]
ONO-3708 DM84IW9 Discovery agent N.A. Investigative [39]
ONO-8809 DM5BMA9 Thrombosis DB61-GB90 Investigative [40]
PGH2 DMZFVGC Discovery agent N.A. Investigative [35]
S 18204 DM2FC5V Discovery agent N.A. Investigative [41]
SQ 26655 DMRP42B Discovery agent N.A. Investigative [42]
SQ-29548 DM9G3UD Discovery agent N.A. Investigative [13]
STA2 DMIYJ2M Discovery agent N.A. Investigative [37]
U-44069 DM0DMNS Discovery agent N.A. Investigative [43]
U46619 DM13FX4 Discovery agent N.A. Investigative [13]
[125I]BOP DMV6I7H Discovery agent N.A. Investigative [44]
[125I]PTA-OH DMROKJP Discovery agent N.A. Investigative [45]
[125I]SAP DM1DXHG Discovery agent N.A. Investigative [38]
[125I]SQ-29548 DM0GKMA Discovery agent N.A. Investigative [46]
------------------------------------------------------------------------------------
⏷ Show the Full List of 27 Investigative Drug(s)

Molecular Expression Atlas (MEA) of This DTT

Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This DTT
Disease Name ICD 11 Studied Tissue p-value Fold-Change Z-score
Asthma CA23 Nasal and bronchial airway 2.78E-04 -0.11 -0.31
------------------------------------------------------------------------------------

References

1 Chronic ouabain treatment exacerbates blood pressure elevation in spontaneously hypertensive rats: the role of vascular mechanisms. J Hypertens. 2009 Jun;27(6):1233-42.
2 Flow after prostaglandin E1 is mediated by receptor-coupled adenylyl cyclase in human anterior segments. Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2622-6.
3 Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
4 Participation in cysteinyl leukotrienes and thromboxane A2 in nasal congestion model in Brown Norway rats. Int Immunopharmacol. 2007 Nov;7(11):1483-7.
5 Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers. J Pharm Pharmacol. 1996 Apr;48(4):380-5.
6 Ifetroban sodium: an effective TxA2/PGH2 receptor antagonist. Cardiovasc Drug Rev. 2001 Summer;19(2):97-115.
7 AT-1 receptor antagonism modifies the mediation of endothelin-1, thromboxane A2, and catecholamines in the renal constrictor response to angiotensin II. Kidney Int Suppl. 2005 Jan;(93):S3-9.
8 Effects of KP-496, a novel dual antagonist for leukotriene D4 and thromboxane A2 receptors, on contractions induced by various agonists in the guinea pig trachea. Allergol Int. 2006 Dec;55(4):403-10.
9 ClinicalTrials.gov (NCT00229437) Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy. U.S. National Institutes of Health.
10 DTTX30, a combined thromboxane receptor antagonist and thromboxane synthetase inhibitor, prevents coronary thrombosis in anesthetized dogs. Basic Res Cardiol. 1997 Jun;92(3):181-90.
11 G 619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, inhibits tumor necrosis factor-alpha biosynthesis. Eur J Pharmacol. 1995 Nov 3;286(1):31-9.
12 In vitro pharmacologic profile of YM158, a new dual antagonist for LTD4 and TXA2 receptors. J Pharmacol Exp Ther. 1998 Nov;287(2):633-9.
13 The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
14 The effect of a novel thromboxane A2 (TXA2) receptor antagonist (S-1452) on the antigen-induced bronchoconstriction and airway hyperresponsiveness in guinea pigs. Prostaglandins Leukot Essent Fatty Acids. 1993 May;48(5):343-9.
15 Synthesis and thromboxane A2/prostaglandin H2 receptor antagonistic activity of phenol derivatives. J Med Chem. 1992 Jun 12;35(12):2202-9.
16 Thromboxane A2 inhibition: therapeutic potential in bronchial asthma. Am J Respir Med. 2002;1(1):11-7.
17 Terutroban and endothelial TP receptors in atherogenesis. Med Sci (Paris). 2006 Apr;22(4):437-43.
18 The effects of thromboxane receptor blockade on platelet aggregation and digital skin blood flow in patients with secondary Raynaud's syndrome. Rheumatol Int. 1991;11(4-5):163-8.
19 Effects of the novel thromboxane (TXA2) receptor antagonist linotroban on inulin and para-aminohippuric acid clearances in the conscious male and female rat. Arzneimittelforschung. 1997 Sep;47(9):1026-30.
20 Influence of SQ 30741 on thromboxane receptor-mediated responses in the feline pulmonary vascular bed. J Appl Physiol (1985). 1991 Nov;71(5):2012-8.
21 Pharmacokinetic and pharmacodynamic properties of a new thromboxane receptor antagonist (Z-335) after single and multiple oral administrations to healthy volunteers. J Clin Pharmacol. 2002 Jul;42(7):782-90.
22 Blood pressure effects of thromboxane A2 blockade in spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 1993 Nov;20(11):679-87.
23 Azulene derivatives as TXA2/PGH2 receptor antagonists--II. Synthesis and biological activity of 6-mono- and 6-dihydroxylated-isopropylazulenes. Bioorg Med Chem. 1996 Apr;4(4):575-91.
24 Antithrombotic effects of KW-3635, a thromboxane A2-receptor antagonist, in guinea pigs. Jpn J Pharmacol. 1994 Jun;65(2):93-8.
25 Novel synthesis and biochemical properties of an [125I]-labeled photoaffinity probe for thromboxane A2/prostaglandin H2 receptors. J Med Chem. 1991 Apr;34(4):1511-4.
26 The effect of a TXA2 receptor antagonist ON-579 on experimental allergic reactions. Prostaglandins Leukot Essent Fatty Acids. 1995 Aug;53(2):123-33.
27 Conformationally-restricted analogs of TXA2 antagonist SQ 33,961: Receptor binding conformation of the carboxyl sidechain. Bioorganic & Medicinal Chemistry Letters Volume 1, Issue 9, 1991, Pages 465-470.
28 The PGI2-analogue iloprost and the TXA2-receptor antagonist sulotroban synergistically inhibit TXA2-dependent platelet activation. Prostaglandins. 1988 Dec;36(6):751-60.
29 Synthesis and structure-activity relationships of novel benzimidazole and imidazo[4,5-b]pyridine acid derivatives as thromboxane A2 receptor antagonists. J Med Chem. 1993 Apr 30;36(9):1175-87.
30 Effects of vapiprost, a novel thromboxane receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tissue-type plasminogen activator.. Br J Pharmacol. 1992 July; 106(3): 533-538.
31 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004057)
32 Difluorothromboxane A2 and stereoisomers: stable derivatives of thromboxane A2 with differential effects on platelets and blood vessels. Proc Natl Acad Sci U S A. 1989 Jul;86(14):5600-4.
33 Evidence for human thromboxane receptor heterogeneity using a novel series of 9,11-cyclic carbonate derivatives of prostaglandin F2 alpha. Br J Pharmacol. 1996 Mar;117(6):1171-80.
34 Synthesis and pharmacological evaluation of novel nitrobenzenic thromboxane modulators as antiplatelet agents acting on both the alpha and beta iso... J Med Chem. 2006 Jun 15;49(12):3701-9.
35 Effects of KW-3635, a novel dibenzoxepin derivative of a selective thromboxane A2 antagonist, on human, guinea pig and rat platelets. Jpn J Pharmacol. 1992 Jul;59(3):357-64.
36 EP 171: a high affinity thromboxane A2-mimetic, the actions of which are slowly reversed by receptor blockade. Br J Pharmacol. 1989 Apr;96(4):875-87.
37 Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
38 7-[(1R,2S,3S,5R)-6,6-dimethyl-3-(4- iodobenzenesulfonylamino)bicyclo[3.1.1]hept-2-yl]-5(Z)-heptenoic acid: a novel high-affinity radiolabeled antagonist for platelet thromboxane A2/prostaglandin H2 receptors. J Pharmacol Exp Ther. 1992 Aug;262(2):632-7.
39 Characterization of U46619 binding in unactivated, intact human platelets and determination of binding site affinities of four TXA2/PGH2 receptor antagonists (13-APA, BM 13.177, ONO 3708 and SQ 29,548). Thromb Res. 1986 Feb 15;41(4):471-81.
40 Anti-thrombotic effect of ONO-8809, a novel TXA2/PG endoperoxide receptor antagonist. Adv Prostaglandin Thromboxane Leukot Res. 1991;21B:599-602.
41 Antithrombotic effects of S 18886, a novel orally active thromboxane A2 receptor antagonist. J Thromb Haemost. 2004 Mar;2(3):492-8.
42 Synthesis and in vitro pharmacology of 7-oxabicyclo[2.2.1]heptane analogues of thromboxane A2/PGH2. J Med Chem. 1985 Nov;28(11):1580-90.
43 cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
44 Characterization of an 125I-labeled thromboxane A2/prostaglandin H2 receptor agonist. J Pharmacol Exp Ther. 1989 Nov;251(2):557-62.
45 Binding of thromboxane A2/prostaglandin H2 agonists to human platelets. Br J Pharmacol. 1987 May;91(1):223-7.
46 Characterization of [5,6-3H]SQ 29,548 as a high affinity radioligand, binding to thromboxane A2/prostaglandin H2-receptors in human platelets. J Pharmacol Exp Ther. 1988 Jun;245(3):786-92.